Another considerable advance in breast cancer treatment was the introduction of monoclonal antibody therapy in the mid-2000s against HER2+ breast cancer, which is a highly lethal type of breast cancer and contributes to 20–30% of all breast cancers [34]. The gene discussed is ERBB2; the disease is breast carcinoma.